Program
lorlatinib
Also written as “Lorlatinib”, “PF-06463922” and “Lorlatinib 50 mg”.
Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Neoplasms · Carcinoma · Renal Insufficiency, led by 4 companies.
Drug pageLorlatinib: every studyAll 45 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Pfizerits history only | 173 open or running | phase 4since Apr 22, 2020 | Oct 16, 2013 | Nov 30, 2028NCT06487078 |
| CStone Pharmaceuticalsits history only | 11 open or running | phase 2since Mar 17, 2022 | Mar 17, 2022 | none ahead |
| Hoffmann-La Rocheits history only | 11 open or running | phase 1since May 14, 2026 | May 14, 2026 | Aug 31, 2030phase 1 · NCT07617337 |
| Strata Oncologyits history only | 10 open or running | phase 2since Oct 1, 2021 | Oct 1, 2021 | none ahead |
Also a collaborator on its studies: Merck and Gilead Sciences.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
Not listed one by one: 6 earlier studies, Oct 16, 2013 to Jul 17, 2016.
- Dec 9, 2015Named lorlatinibINNProposed as its International Nonproprietary Name in WHO's List 114 · before, PF-06463922
- Jan 20, 2017Phase 3 study in Carcinoma, Non-Small-Cell LungPfizer · NCT03052608 · 296 enrolled · United States, Argentina, Australia and more
- May 17, 2017Phase 1 study in Carcinoma, Non-Small-Cell LungPfizer · NCT03184168 · 6 enrolled · United States
- May 18, 2018Phase 1 study in Renal InsufficiencyPfizer · NCT03542305 · 29 enrolled · United States
- Sep 24, 2018Phase 1 study in NeoplasmsPfizer · NCT03726333 · 1 enrolled · United States
- Feb 5, 2019Phase 2 study in Carcinoma, Non-Small-Cell LungPfizer · NCT03909971 · 109 enrolled · China
- May 22, 2019Phase 1 study in AdultPfizer · NCT03961997 · 16 enrolled · Belgium
- Apr 22, 2020Phase 4 study in CarcinomaPfizer · NCT04362072 · 71 enrolled · United States, India, Italy and more
- Aug 21, 2020Phase 4 study in Advanced Non-Small Cell Lung CancerPfizer · NCT04541706 · 100 enrolled · India
- Oct 1, 2021Strata Oncology’s first study: phase 2 study in NeoplasmsNew to Strata OncologyStrata Oncology · NCT05097599 · 11 enrolled · United States
- Nov 22, 2021Phase 4 study in Carcinoma, Non-Small-Cell LungPfizer · NCT05144997 · 76 enrolled · United States, China, France and more
- Jan 24, 2022Phase 1 study in Moderate Hepatic ImpairmentPfizer · NCT05224609 · 21 enrolled · United States
- Mar 17, 2022CStone Pharmaceuticals’ first study: phase 2 study in Advanced or Metastatic ROS1-Positive Non-Small Cell Lung CancerNew to CStone PharmaceuticalsCStone Pharmaceuticals · NCT05297890 · 70 enrolled · China
- Jun 5, 2024No phase study in ALK+ Non-Small-Cell Lung CarcinomaPfizer · NCT06487078 · 90 planned · France
- May 14, 2026Hoffmann-La Roche’s first study: phase 1 study in ALK Positive Non-small Cell Lung CancerNew to Hoffmann-La RocheHoffmann-La Roche · NCT07617337 · 102 planned · United States, Japan
Ahead
- Nov 30, 2028Primary completion: no phase study in ALK+ Non-Small-Cell Lung CarcinomaPfizer · NCT06487078
- Oct 25, 2029Primary completion: phase 4 study in Carcinoma, Non-Small-Cell LungPfizer · NCT05144997
- Aug 31, 2030Primary completion: phase 1 study in ALK Positive Non-small Cell Lung CancerHoffmann-La Roche · NCT07617337
TargetBeta
“An orally available, ATP-competitive inhibitor of the receptor tyrosine kinases, anaplastic lymphoma kinase (ALK) and C-ros oncogene 1 (Ros1), ”NCIt, by rule
“ALK tyrosine kinase receptor inhibitor; EML4-ALK inhibitor”ChEMBL 37, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Crizotinibrule | Pfizer | phase 4 | 31 |
Studies
All 20 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07617337ALK Positive Non-small Cell Lung Cancer · United States, Japan | 1 | Recruiting | Hoffmann-La Roche | Aug 31, 2030 | 102 |
| NCT06487078ALK+ Non-Small-Cell Lung Carcinoma · France | – | Recruiting | Pfizer | Nov 30, 2028 | 90 |
| NCT05297890Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer · China | 2 | Active, not recruiting | CStone Pharmaceuticals | Dec 26, 2023 | 70 |
| NCT05224609Moderate Hepatic Impairment · United States | 1 | Completed | Pfizer | Aug 13, 2024 | 21 |
| NCT05144997Carcinoma, Non-Small-Cell Lung · United States, China, France and more | 4 | Active, not recruiting | Pfizer | Oct 25, 2029 | 76 |
| NCT05097599Neoplasms · United States | 2 | Terminated | Strata Oncology | Jun 12, 2024 | 11 |
| NCT04541706Advanced Non-Small Cell Lung Cancer · India | 4 | Completed | Pfizer | Jul 20, 2022 | 100 |
| NCT04362072Carcinoma · United States, India, Italy and more | 4 | Completed | Pfizer | May 29, 2024 | 71 |
| NCT03961997Adult · Belgium | 1 | Completed | Pfizer | Dec 9, 2019 | 16 |
| NCT03909971Carcinoma, Non-Small-Cell Lung · China | 2 | Completed | Pfizer | Aug 10, 2020 | 109 |
| NCT03726333Neoplasms · United States | 1 | Terminated | Pfizer | Jul 8, 2021 | 1 |
| NCT03542305Renal Insufficiency · United States | 1 | Completed | Pfizer | Feb 20, 2020 | 29 |
| NCT03184168Carcinoma, Non-Small-Cell Lung · United States | 1 | Completed | Pfizer | Aug 7, 2017 | 6 |
| NCT03052608Carcinoma, Non-Small-Cell Lung · United States, Argentina, Australia and more | 3 | Active, not recruiting | Pfizer | Mar 20, 2020 | 296 |
| NCT02838264Healthy · Belgium | 1 | Completed | Pfizer | Mar 31, 2017 | 16 |
| NCT02804399Healthy · United States | 1 | Completed | Pfizer | Oct 2016 | 12 |
| NCT02584634Carcinoma, Non-Small-Cell Lung · United States, Australia, Japan and more | 2 | Terminated | Pfizer | Feb 2, 2021 | 43 |
| NCT02569554Healthy · Belgium | 1 | Completed | Pfizer | Apr 2016 | 27 |
| NCT02564562Healthy · United States | 1 | Completed | Pfizer | Nov 2015 | 6 |
| NCT01970865Carcinoma, Non-Small-Cell Lung · United States, Australia, Belgium and more | 2 | Completed | Pfizer | Mar 15, 2017 | 364 |
How it is read
Names in the registry
- “Lorlatinib”, 10 entries
- “PF-06463922”, 8 entries
- “lorlatinib”, 6 entries
- “Lorlatinib 50 mg”, 1 entry
- “Lorlatinib 75 mg”, 1 entry
Conditions, from the studies’ own filings
- Carcinoma, Non-Small-Cell Lung, 10 studies
- Neoplasms, 2 studies
- Carcinoma, 1 study
- Renal Insufficiency, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.